skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreProduct loginProductLogin
Global Search Configuration

As Prexton Therapeutics prepares to move its lead compound foliglurax into Phase II trials as a symptomatic treatment for Parkinson’s disease, CEO Francois Conquet talks to Scrip about the company's technology and its future. Prexton raised EUR 29 million via a series B financing earlier this year to progress foliglurax, a metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM), into Phase II trials. A European Phase II trial is expected to enroll its first patient in June and will be completed by the end of 2018. A US trial is also planned. After Phase II, Conquet hopes the company will be able to license the compound to a big pharma for Phase III development.

 

 

Read also

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Start a free trial

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact Sales

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Contact Customer Services

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now